NBY
Novabay·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Stock Price Surged Significantly
Ample Liquidity
Dark Cloud Cover
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NBY
Novabay Pharmaceuticals, Inc.
A developer of non-antibiotic and anti-infective products for the eye care and skin care
2000 Powell Street, Suite 1150, Emeryville, California 94608
--
Novabay Pharmaceuticals, Inc., was incorporated under the laws of the State of California on January 19, 2000. In June 2010, the company changed its state of incorporation and is now incorporated under the laws of Delaware. The company develops and markets scientifically created and clinically proven eye care, skin care and wound care products. The Company's lead products, Avenova Antibacterial Cover and Mascara, have been shown in laboratory tests to have a wide range of antibacterial properties and can remove foreign substances, including microorganisms and debris, from the skin around the eyes, including the eyelids. Avenova Spray is formulated in their proprietary, stable, pure hypochlorous acid form and is approved by the U.S. Food and Drug Administration for sale in the United States.
Company Financials
EPS
NBY has released its 2025 Q2 earnings. EPS was reported at -0.34, versus the expected 0.01, missing expectations. The chart below visualizes how NBY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NBY has released its 2025 Q3 earnings report, with revenue of 521.00K, reflecting a YoY change of -78.66%, and net profit of -1.29M, showing a YoY change of -6.68%. The Sankey diagram below clearly presents NBY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
